Blazsek I, Mathé G, Comisso M, Kitasato H, Umezawa K, Umezawa H
Institut du Cancer et d'Immunogénétique (Univ. Paris-Sud, Association Claude-Bernard & ARC), Hôpital Paul-Brousse, Villejuif, France.
Biomed Pharmacother. 1989;43(4):267-70. doi: 10.1016/0753-3322(89)90007-3.
Acute toxicity to the hematopoietic cell renewal system is a critical side effect of most anticancer agents. Here we compared the effects of FAD-104 to those of the parent compound adriamycin (ADM) and of epi-adriamycin (epi-ADM) on the growth and differentiation of normal as well as leukemic human myeloid progenitor cells. FAD-104 was less toxic to myeloid colony-forming cells (GM-CFU) than ADM or epi-ADM. In addition, FAD-104 but not ADM induced a clonal down-grading in both normal and leukemic blast cells, and it stimulated the terminal differentiation of myeloid leukemia cells. Therefore, FAD-104 may be useful in the treatment of some forms of myeloid leukemia.
对造血细胞更新系统的急性毒性是大多数抗癌药物的关键副作用。在此，我们比较了FAD - 104与母体化合物阿霉素（ADM）及表阿霉素（表阿霉素）对正常和白血病人类髓系祖细胞生长和分化的影响。FAD - 104对髓系集落形成细胞（GM - CFU）的毒性低于ADM或表阿霉素。此外，FAD - 104而非ADM可诱导正常和白血病原始细胞的克隆降级，并刺激髓系白血病细胞的终末分化。因此，FAD - 104可能对某些形式的髓系白血病治疗有用。
